Top Markets
Coin of the day
Kadimastem Ltd Kadimastem Ltd

Kadimastem Ltd

KDST
Rank in Stocks #41016
Kadimastem Ltd is a biopharmaceutical company focused on pioneering... Kadimastem Ltd is a biopharmaceutical company focused on pioneering regenerative medical treatments. These therapies are developed using cells sourced from human embryonic stem cells, primarily targeting neurodegenerative diseases. Its development pipeline features AstroRx, a clinical-grade human astrocyte product currently undergoing Phase 1/2a clinical trials for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. Additionally, the company is advancing IsletRx, a clinical-grade pancreatic islet cell therapy intended for the treatment of diabetes. Incorporated in 2008, Kadimastem is headquartered in Ness Ziona, Israel.
Share Price
$12.16
Last synced: 2025-10-30
Market Cap
$50.98K
Change (1 day)
-0.10%
Change (1 year)
56.95%
Country
IL
Trade Kadimastem Ltd (KDST)

Category

P/B ratio for Kadimastem Ltd (KDST)
P/B ratio as of 2026 TTM: 0
According to Kadimastem Ltd latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Kadimastem Ltd from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE